[The effect of antileukemic drugs on superoxide (O2-) production by human neutrophils]. 1987

M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D009279 Naphthacenes Polyacenes with four ortho-fused benzene rings in a straight linear arrangement. This group is best known for the subclass called TETRACYCLINES. Tetracenes,Benz(b)Anthracenes
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013481 Superoxides Highly reactive compounds produced when oxygen is reduced by a single electron. In biological systems, they may be generated during the normal catalytic function of a number of enzymes and during the oxidation of hemoglobin to METHEMOGLOBIN. In living organisms, SUPEROXIDE DISMUTASE protects the cell from the deleterious effects of superoxides. Superoxide Radical,Superoxide,Superoxide Anion
D015250 Aclarubicin An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity. Aclacinomycin A,Aclacin,Aclaplastin,MA-144A1,NSC-208734,MA 144A1,MA144A1,NSC 208734,NSC208734

Related Publications

M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima
March 1984, Sangyo igaku. Japanese journal of industrial health,
M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima
December 1988, Prostaglandins, leukotrienes, and essential fatty acids,
M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima
January 1989, Cardiology,
M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima
January 2000, Regional anesthesia and pain medicine,
M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima
December 1983, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima
August 1988, The Journal of dermatology,
M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima
January 1991, Free radical research communications,
M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima
April 1992, Annals of the New York Academy of Sciences,
M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima
October 1983, Acta medica Okayama,
M Katoh, and T Shirai, and M Umeda, and R Yamaguchi, and H Kaneko, and I Ishikawa, and M Yamauchi, and N Kojima
December 1984, Inflammation,
Copied contents to your clipboard!